Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study

  • Authors:
    • M. Jerkeman
    • P. Aman
    • E. Cavallin-Stahl
    • E. Torlakovic
    • M. Akerman
    • F. Mitelman
    • T. Fioretos
  • View Affiliations

  • Published online on: January 1, 2002     https://doi.org/10.3892/ijo.20.1.161
  • Pages: 161-165
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of this study was to investigate the prognostic implications of BCL6 rearrangement in a uniformly treated population of patients with diffuse large B-cell lymphoma (DLBCL) and to characterise the relationship between BCL6 rearrangement and prognostic factors. A total of 269 patients with DLBCL entered a randomised trial comparing the chemotherapy regimen CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) to the MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) regimen. In 44 cases, frozen tissue was available for assessment of BCL6 status by Southern blot analysis. BCL6 was rearranged in six of 43 evaluable cases (14%), and was associated with elevated lactate dehydrogenase (LDH), and a higher patient age. No association between BCL6 status and expression of BCL2, Ki-67 or TP53 was found. Patients presenting with BCL6 rearrangement displayed a weak trend towards better overall and failure-free survival (67 and 67% at 5 years), compared to patients with germline BCL6 (63 and 52%), but the difference was not statistically significant. In accordance with previously published series, the presence of BCL6 rearrangement does not define a prognostically distinct subgroup of DLBCL. Assessment of BCL6 status may, however, be of clinical interest when related to other prognostic variables.

Related Articles

Journal Cover

January 2002
Volume 20 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jerkeman M, Aman P, Cavallin-Stahl E, Torlakovic E, Akerman M, Mitelman F and Fioretos T: Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. Int J Oncol 20: 161-165, 2002
APA
Jerkeman, M., Aman, P., Cavallin-Stahl, E., Torlakovic, E., Akerman, M., Mitelman, F., & Fioretos, T. (2002). Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. International Journal of Oncology, 20, 161-165. https://doi.org/10.3892/ijo.20.1.161
MLA
Jerkeman, M., Aman, P., Cavallin-Stahl, E., Torlakovic, E., Akerman, M., Mitelman, F., Fioretos, T."Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study". International Journal of Oncology 20.1 (2002): 161-165.
Chicago
Jerkeman, M., Aman, P., Cavallin-Stahl, E., Torlakovic, E., Akerman, M., Mitelman, F., Fioretos, T."Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study". International Journal of Oncology 20, no. 1 (2002): 161-165. https://doi.org/10.3892/ijo.20.1.161